Malecki Law is investigating possible unsuitability claims against stock brokers and financial advisors who sold shares of Amarin to investors for whom the stock was not appropriate.
Amarin is a biopharmaceutical company based out of New Jersey. The company’s primary business involves the development and marketing of medicines used to treat cardiovascular disease. Amarin is best known as the company that developed the pharmaceutical drug Vascepa.
Over the past few years, Amarin has been reportedly seeking various FDA approvals for Vascepa. During the past four to five years, the shares of Amarin have shown great volatility. The shares have gone from roughly $1 per share in February of 2010 up to $19 per share in May of 2011 and back down to just more than $1 per share today. In October 2013, share prices went from more than $7 per share to just over $2 per share in less than two weeks. Again this past October, share prices dropped roughly 50% in only one month’s time.
As a result, investors who were sold Amarin by their financial advisor may have experienced crushing losses. It is believed that some financial advisors may have been advising clients to buy Amarin in the run up to major announcements by the company. When negative news came out, the stock price fell dramatically, causing significant losses to investors.
Financial Industry Regulatory Authority (“FINRA”) rules expressly prohibit registered financial advisors from selling unsuitable investments to the public. Therefore, investors who bought Amarin at the recommendation of a financial advisor may be able to recover some or all of their losses.
It is the right of any and all investors who believe they may have suffered losses as a result of recommendations of their financial advisor to contact our offices to explore their legal rights and options. If you or a family member invested in Amarin, contact the securities fraud lawyers at Malecki Law for a free consultation and case evaluation at (212) 943-1233.
Malecki Law takes a proactive and informed approach to the financial news of today: actively engaging in fact-finding analysis on prospective cases from around the world. Our thorough knowledge of securities law’s history and fine points makes us ideal consultants for investors who have suffered losses due to misadvice from their broker or other financial counsel.